Antiemesis

David S. Ettinger; Debra K. Armstrong; Sally Barbour; Michael J. Berger; Philip J. Bierman; Bob Bradbury; Georgianna Ellis; Steve Kirkegaard; Dwight D. Kloth; Mark G. Kris; Dean Lim; Michael Anne Markiewicz; Lida Nabati; Carli Nesheiwat; Hope S. Rugo; Steven M. Sorscher; Lisa Stucky-Marshal; Barbara Todaro; Susan Urba

doi:10.6004/jnccn.2009.0039

Antiemesis

David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Lida Nabati, Carli Nesheiwat, Hope S. Rugo, Steven M. Sorscher, Lisa Stucky-Marshal, Barbara Todaro, Susan Urba

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

Original language	English (US)
Pages (from-to)	572-595
Number of pages	24
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	7
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2009.0039
State	Published - May 2009
Externally published	Yes

Keywords

5-HT3-receptor antagonists
Antiemesis
Chemotherapy-induced
NCCN Clinical Practice Guidelines
NK-1-receptor antagonists
Nausea and vomiting

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2009.0039

Cite this

Ettinger, D. S., Armstrong, D. K., Barbour, S., Berger, M. J., Bierman, P. J., Bradbury, B., Ellis, G., Kirkegaard, S., Kloth, D. D., Kris, M. G., Lim, D., Markiewicz, M. A., Nabati, L., Nesheiwat, C., Rugo, H. S., Sorscher, S. M., Stucky-Marshal, L., Todaro, B., & Urba, S. (2009). Antiemesis. JNCCN Journal of the National Comprehensive Cancer Network, 7(5), 572-595. https://doi.org/10.6004/jnccn.2009.0039

Ettinger, DS, Armstrong, DK, Barbour, S, Berger, MJ, Bierman, PJ, Bradbury, B, Ellis, G, Kirkegaard, S, Kloth, DD, Kris, MG, Lim, D, Markiewicz, MA, Nabati, L, Nesheiwat, C, Rugo, HS, Sorscher, SM, Stucky-Marshal, L, Todaro, B & Urba, S 2009, 'Antiemesis', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 5, pp. 572-595. https://doi.org/10.6004/jnccn.2009.0039

@article{d9a5cf8fe7ae4ab684630402ccffa826,

title = "Antiemesis",

abstract = "Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.",

keywords = "5-HT3-receptor antagonists, Antiemesis, Chemotherapy-induced, NCCN Clinical Practice Guidelines, NK-1-receptor antagonists, Nausea and vomiting",

author = "Ettinger, {David S.} and Armstrong, {Debra K.} and Sally Barbour and Berger, {Michael J.} and Bierman, {Philip J.} and Bob Bradbury and Georgianna Ellis and Steve Kirkegaard and Kloth, {Dwight D.} and Kris, {Mark G.} and Dean Lim and Markiewicz, {Michael Anne} and Lida Nabati and Carli Nesheiwat and Rugo, {Hope S.} and Sorscher, {Steven M.} and Lisa Stucky-Marshal and Barbara Todaro and Susan Urba",

year = "2009",

month = may,

doi = "10.6004/jnccn.2009.0039",

language = "English (US)",

volume = "7",

pages = "572--595",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

TY - JOUR

T1 - Antiemesis

AU - Ettinger, David S.

AU - Armstrong, Debra K.

AU - Barbour, Sally

AU - Berger, Michael J.

AU - Bierman, Philip J.

AU - Bradbury, Bob

AU - Ellis, Georgianna

AU - Kirkegaard, Steve

AU - Kloth, Dwight D.

AU - Kris, Mark G.

AU - Lim, Dean

AU - Markiewicz, Michael Anne

AU - Nabati, Lida

AU - Nesheiwat, Carli

AU - Rugo, Hope S.

AU - Sorscher, Steven M.

AU - Stucky-Marshal, Lisa

AU - Todaro, Barbara

AU - Urba, Susan

PY - 2009/5

Y1 - 2009/5

N2 - Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

AB - Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

KW - 5-HT3-receptor antagonists

KW - Antiemesis

KW - Chemotherapy-induced

KW - NCCN Clinical Practice Guidelines

KW - NK-1-receptor antagonists

KW - Nausea and vomiting

UR - http://www.scopus.com/inward/record.url?scp=66749129673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749129673&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2009.0039

DO - 10.6004/jnccn.2009.0039

M3 - Review article

C2 - 19460282

AN - SCOPUS:66749129673

SN - 1540-1405

VL - 7

SP - 572

EP - 595

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Antiemesis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this